We are live on ! Find out more
5VM

5AM Venture Management Portfolio holdings

AUM $360M
1-Year Est. Return 345.76%
This Fund
S&P 500
This Quarter Est. Return
+17.67%
1 Year Est. Return
+345.76%
3 Year Est. Return
+491.51%
5 Year Est. Return
+330.26%
10 Year Est. Return
–
AUM
$484M
AUM Growth
+$36.9M
Cap. Flow
+$8.73M
Cap. Flow %
1.8%
Top 10 Hldgs %
68.13%
Holding
29
New
1
Increased
3
Reduced
4
Closed
1

Top Buys

Rank Stock Value
1
ARTV
Artiva Biotherapeutics
ARTV
+$27.3M
2
EYPT icon
EyePoint Inc
EYPT
+$8.78M
3
CNTA
Centessa Pharmaceuticals
CNTA
+$490K
4
BHVN icon
Biohaven
BHVN
+$350K

Top Sells

Rank Stock Value
1
ELVN icon
Enliven Therapeutics
ELVN
+$19.9M
2
QTTB icon
Q32 Bio
QTTB
+$4.52M
3
COGT icon
Cogent Biosciences
COGT
+$2.23M
4
SKYE icon
Skye Bioscience
SKYE
+$1.49M
5
DNTH icon
Dianthus Therapeutics
DNTH
+$37.5K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRSN
26
DELISTED
Mersana Therapeutics
MRSN
$2.47M 0.51%
52,200
– –
ZNTL icon
27
Zentalis Pharmaceuticals
ZNTL
$342M
$1.8M 0.37%
490,000
– –
CDTX
28
DELISTED
Cidara Therapeutics
CDTX
$610K 0.13%
56,725
– –
QTTB icon
29
Q32 Bio
QTTB
$457M
– –
-251,994
Closed -$4.52M
1
2

Similar funds

LSC
Logan Stone Capital Chicago, Illinois $360M AUM 9.71% 1-Year Est. Return
WIP
WealthCare Investment Partners Portsmouth, Rhode Island $360M AUM 19.98% 1-Year Est. Return
RA
RR Advisors Dallas, Texas $360M AUM 28.52% 1-Year Est. Return
SWM
SK Wealth Management Providence, Rhode Island $360M AUM 14.81% 1-Year Est. Return
NC
Naman Capital Sao Paulo, Brazil $360M AUM 27.43% 1-Year Est. Return
MCM
Monimus Capital Management Woodbridge, New Jersey $361M AUM 21.17% 1-Year Est. Return
KLWA
Kelly Lawrence W & Associates Pasadens, California $360M AUM 16.9% 1-Year Est. Return
PWC
PYA Waltman Capital Knoxville, Tennessee $361M AUM 9.49% 1-Year Est. Return

5AM Venture Management's Q3 2024 Portfolio in Review

As of Q3 2024, 5AM Venture Management held 29 positions worth $484M, up 8.3% from $447M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

5AM Venture Management's Q3 2024 filing shows 1 new, 3 increased, 4 reduced and 1 closed positions. Its largest new stake was Artiva Biotherapeutics: 2,353,304 shares worth $36.4M. The largest sale was Enliven Therapeutics, an estimated $19.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • 5AM Venture Management's largest Q3 2024 buy was Artiva Biotherapeutics: 2,353,304 shares worth $36.4M.
  • 5AM Venture Management added most to EyePoint Inc in Q3 2024, an estimated $8.78M increase.
  • 5AM Venture Management's biggest Q3 2024 reduction was Enliven Therapeutics, cutting an estimated $19.9M.
  • 5AM Venture Management fully exited Q32 Bio in Q3 2024, selling an estimated $4.52M.
  • 5AM Venture Management's ten largest holdings make up 68% of its $484M portfolio in Q3 2024.
  • 5AM Venture Management opened 1 new position and closed 1 in Q3 2024.
  • 5AM Venture Management's portfolio value rose 8.3% quarter-over-quarter to $484M.

Based on 5AM Venture Management's 13F filing for Q3 2024, filed 14 Nov 2024.